The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa.
about
The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysisVaccination greatly reduces disease, disability, death and inequity worldwideHepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C.Circulating tumor DNA in hepatocellular carcinoma: trends and challengesKASL clinical practice guidelines: management of chronic hepatitis BReasons why West Africa continues to be a hotbed for hepatocellular carcinomaDiagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-AnalysisPartially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.The challenge of AIDS-related malignancies in sub-Saharan Africa.Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.Increase in female liver cancer in the Gambia, West Africa: evidence from 19 years of population-based cancer registration (1988-2006)Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.Combined effect of socioeconomic status, viral hepatitis, and lifestyles on hepatocelluar carcinoma risk in KoreaSeroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected GambiansHepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection.Meta-analysis of microsomal epoxide hydrolase gene polymorphism and risk of hepatocellular carcinomaObservational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster doseAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsLinifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia, West AfricaThymic function and T cell parameters in a natural human experimental model of seasonal infectious diseases and nutritional burdenEfficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation programGolgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis.Distribution of HBV genotypes among HBV carriers in Benin:phylogenetic analysis and virological characteristics of HBV genotype ETP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations.Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virusHepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995-2015)Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein.TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The GambiaKASL Clinical Practice Guidelines: Management of chronic hepatitis B.Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma.Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide.The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use.Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia.Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus.
P2860
Q21245094-2BB49126-52FC-4D24-9282-D923ED71C37DQ24648884-7F5A99DB-E13A-456A-903B-6604E29616B0Q24815408-820C9A46-FF85-442B-85BD-1C36933BD91AQ26749417-145CF31E-20C1-4501-9D59-A0AAE71F7BA8Q26752475-00A7400E-13A5-445C-9FB1-22D7FB0B74BDQ26772209-1972748B-362B-4346-9095-EA04271D0A7AQ26863560-955F7CF8-F0D2-4973-B8A4-D9AB15F35F90Q28742762-5FC18020-842B-4F06-B7AD-1E9855255F34Q33523293-0E85691E-CB6A-440C-8869-356B2BE922A2Q33633648-0B95B61B-05BA-4FEC-A658-98879DBCA16BQ33797424-3EE03248-7BB4-4CC4-9154-672C14FE1EFBQ33872289-F60F2B50-1627-46F3-9BF0-B44F3A72B5D2Q33969253-A5B7D45B-60B0-4697-B3F0-4DA95170A221Q34122759-544CEBFD-AB42-46D2-AD61-966563140DFCQ34174489-9A0B9D54-E311-478C-AA77-FE33AB3D84B7Q34485074-A137E172-549C-4DB3-AF3E-BD1A1223CC01Q34602962-3BA1C5CD-9B05-44C3-8A9A-D3D23CC2C940Q34637622-2E514126-5FBE-42D2-8382-DE7A254F9E54Q34730950-E429CD10-291B-4DB8-B874-C83155505F08Q34786090-97FB4811-F0B1-4EBF-8A06-8863E8D42732Q34918154-B1DBA5B1-45E3-4F56-B4EC-A106D0C01783Q35010094-D2372200-D287-4097-B569-DC76B9E3257AQ35074312-9850C8BE-2F83-48E3-92E8-7D7337333D84Q35084497-D99BD439-7785-473F-8F66-C187ACC7465EQ35159505-719FE42A-E9C3-4F6E-9D63-5F6F82388D05Q35165939-98D6077B-5823-46A1-80E7-0A47A23FEF9CQ35173311-62E86DA7-9E68-4FCB-96B0-E862A991086EQ35492635-CC98D067-F9B8-4483-A995-F6A57ECC89DFQ35590977-563B785F-0AE8-456D-BA21-A7F33104A7BCQ35833159-8ECED721-5AE8-42B7-8CF5-F85B34126F83Q35961475-9D16B6F6-DB8B-451B-879A-E4AC2969FDC8Q35990415-0D982104-7DA8-4982-802D-778837EC27DAQ36072589-2DC49339-DE62-4569-A92C-14963D13CAC5Q36153966-0DBC3816-D6AF-49EA-BC05-22D241B32A36Q36198665-10C346E8-7383-4807-A2EF-4C0B7E0A426FQ36454765-FC4AF1C9-C3B0-43FC-A95A-50A7A158D657Q36575228-22BF232E-3BC3-496D-B320-8A984A046017Q36606605-36ECBFFC-7FC2-4762-8BFD-D129F560B38EQ36821936-6712ACFF-53ED-4EF0-91EE-9637494CD8B2Q36845456-D63BB6FC-788C-4459-ACB0-D5065F5A0CC4
P2860
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The Gambia Liver Cancer Study: ...... ular carcinoma in West Africa.
@en
type
label
The Gambia Liver Cancer Study: ...... ular carcinoma in West Africa.
@en
prefLabel
The Gambia Liver Cancer Study: ...... ular carcinoma in West Africa.
@en
P2093
P356
P1433
P1476
The Gambia Liver Cancer Study: ...... ular carcinoma in West Africa.
@en
P2093
Aliu O Akano
Andrew J Hall
Gregory D Kirk
Hilton Whittle
James J Goedert
Maimuna Mendy
Olufunmilayo A Lesi
Ruggero Montesano
P304
P356
10.1002/HEP.20027
P407
P577
2004-01-01T00:00:00Z